New stroke drug TAK-755 enters phase 2 trial – could it reduce brain damage?
NCT ID NCT07392450
First seen Feb 06, 2026 · Last updated May 19, 2026 · Updated 15 times
Summary
This study tests whether a single dose of TAK-755 is safe and helps people recover after an acute ischemic stroke (a clot blocking blood flow to the brain). About 222 adults aged 18–80 will receive either TAK-755 or a placebo, plus standard stroke care. Researchers will monitor for bleeding in the brain and track recovery over 90 days.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE ISCHEMIC STROKE are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Honor Health
RECRUITINGScottsdale, Arizona, 85251, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.